# Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed

> **NCT06815770** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 60 (estimated)

## Conditions studied

- Acute on Chronic Liver Failure

## Interventions

- **DRUG:** Terlipressin Injectable Product

## Key facts

- **NCT ID:** NCT06815770
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06815770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06815770, "Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06815770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*